Novartis' final new build in $23B US expansion Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 30 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one

SPOTLIGHT In Focus Bristol Myers reaches a crossroads as a make-or-break year takes shape

news Bioregnum The R&D 15: The stakes needed to play in the world's biggest drug research groups require very deep pockets Lack of specifics on obesity pill sales hover over Lilly’s first quarter Novartis unveils North Carolina factory as final new build in $23B US expansion

May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA FDA revives oncology advisory panel to debate AstraZeneca drugs •  Updated: AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy •  AstraZeneca rekindles UK relationship, pledges £300M to expand As AbbVie posts more strong Skyrizi sales, Wall Street frets over J&J pill Should pharma be swinging bigger with AI? One top researcher left Genentech so he could try

in case you missed it 1. Chiesi signs $1.9B deal to acquire KalVista and its approved drug 2. GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts 3. After Apellis deal, Biogen looks to fill early-stage pipeline 4. MPM has collected three China drugs so far for its ‘best of both worlds’ strategy 5. Convicted former Harvard scientist rebuilds brain computer lab in China